NO20082474L - Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav - Google Patents

Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav

Info

Publication number
NO20082474L
NO20082474L NO20082474A NO20082474A NO20082474L NO 20082474 L NO20082474 L NO 20082474L NO 20082474 A NO20082474 A NO 20082474A NO 20082474 A NO20082474 A NO 20082474A NO 20082474 L NO20082474 L NO 20082474L
Authority
NO
Norway
Prior art keywords
compound
sulfonate
preparation
montelukast
prepared
Prior art date
Application number
NO20082474A
Other languages
English (en)
Inventor
Marti Bartra Sanmarti
Yolanda Gasanz Guillen
Laura Coppi
Montserrat Monsalva Llagostera
Pedro Talavera Escasany
Original Assignee
Esteve Quimica Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Quimica Sa filed Critical Esteve Quimica Sa
Publication of NO20082474L publication Critical patent/NO20082474L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Quinoline Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Den innbefatter en fremstillingsfremgangsmåte for Montelukast fra en ny intermediatforbindelse med formel (VI) som på forhånd er fremstilt ved omsetting av det korresponderende sulfonatet med l-(merkaptometyl)cyklopropyl)metanol. Forbindelse (VI) omsettes med en Grignard reaktant for å omdanne estergruppen til en tertiær alkohol, fulgt av omdanning av den primære alkoholen til et sulfonat, substitusjon av sulfonatgruppen med en cyanogruppe og til slutt omdanne cyanoforbindelsen til karboksylsyreforbindelsen ved en hydrolysereaksjon for å gi Montelukast. Montelukast kan også fremstilles ved en hydrolysereaksjon med det korresponderende amidet. Den innbefatter også nye mtermediatforbindelser anvendelige i slike fremstillingfremgangsmåter.
NO20082474A 2005-11-04 2008-06-02 Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav NO20082474L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73355305P 2005-11-04 2005-11-04
EP05110348A EP1783117A1 (en) 2005-11-04 2005-11-04 Process for the preparation of a leukotriene antagonist and intermediates thereof
PCT/EP2006/068052 WO2007051828A2 (en) 2005-11-04 2006-11-03 Process for the preparation of a leukotriene antagonist and intermediates thereof

Publications (1)

Publication Number Publication Date
NO20082474L true NO20082474L (no) 2008-06-02

Family

ID=36169064

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20082474A NO20082474L (no) 2005-11-04 2008-06-02 Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav

Country Status (11)

Country Link
US (1) US20080306270A1 (no)
EP (2) EP1783117A1 (no)
JP (1) JP2009514927A (no)
KR (1) KR20080064968A (no)
CN (1) CN101321732B (no)
AU (1) AU2006310536A1 (no)
CA (1) CA2627098A1 (no)
NO (1) NO20082474L (no)
RU (1) RU2402532C2 (no)
WO (1) WO2007051828A2 (no)
ZA (1) ZA200803761B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1904448B1 (en) 2005-07-05 2011-02-02 Teva Pharmaceutical Industries, Ltd. Purification of montelukast
KR101072896B1 (ko) 2007-10-09 2011-10-17 한미홀딩스 주식회사 이온성 액체 매개체를 이용한 몬테루카스트산의 제조 방법
EP2552892A1 (en) 2010-03-31 2013-02-06 KRKA, D.D., Novo Mesto Efficient synthesis for the preparation of montelukast and novel crystalline form of intermediates therein
HUP1000425A2 (en) 2010-08-11 2012-03-28 Richter Gedeon Nyrt Process for the production of montelukast sodium
US8471030B2 (en) 2010-12-06 2013-06-25 Orochem Technologies Inc. Purification of montelukast using simulated moving bed
CN103539714A (zh) * 2012-07-16 2014-01-29 上海朴颐化学科技有限公司 1-巯甲基环丙基乙酸及其中间体的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW448160B (en) * 1993-12-28 2001-08-01 Merck & Co Inc Novel dicyclohexylamine salt and process for the preparation of leukotriene antagonists
US20050107612A1 (en) * 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
US7189853B2 (en) * 2004-04-15 2007-03-13 Dr. Reddy's Laboratories Limited Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (Montelukast) and its pharmaceutically acceptable salts

Also Published As

Publication number Publication date
CN101321732B (zh) 2011-04-13
RU2008122367A (ru) 2009-12-10
CA2627098A1 (en) 2007-05-10
RU2402532C2 (ru) 2010-10-27
KR20080064968A (ko) 2008-07-10
WO2007051828A2 (en) 2007-05-10
EP1948611B1 (en) 2012-05-23
US20080306270A1 (en) 2008-12-11
JP2009514927A (ja) 2009-04-09
EP1948611A2 (en) 2008-07-30
AU2006310536A1 (en) 2007-05-10
EP1783117A1 (en) 2007-05-09
WO2007051828A3 (en) 2007-08-23
ZA200803761B (en) 2009-09-30
CN101321732A (zh) 2008-12-10

Similar Documents

Publication Publication Date Title
NO20082474L (no) Fremgangsmate for fremstilling av en leukotrienantagonist og intermediater derav
JP2009533369A5 (no)
JP2012251113A5 (no)
CN111875538B (zh) 一种匹伐他汀叔丁酯的合成方法
TW200726754A (en) Chemical process
JP2009527517A5 (no)
TW201035052A (en) Process for manufacturing substituted 5-methoxymethylpyridine-2,3-dicarboxylic acid derivatives
NO20080080L (no) Organiske forbindelser
US8030491B2 (en) Process and intermediate for preparation of donepezil
US7619095B2 (en) Process for the preparation of indolone derivative
CN107365262A (zh) 一种5,5-二甲基-2-氰基环戊酮的制备方法
RU2009128032A (ru) Способ получения абакавира
CN111072630A (zh) 一种溴代吡唑类化合物中间体的制备方法与应用
RU2012118499A (ru) Способ получения пиразинонового ингибитора тромбина и промежуточных соединений для его получения
CN108840814A (zh) 一种8-氧代-2,6,9-三氮杂螺[4．5]癸烷-2-羧酸叔丁酯制备方法
JP2008007484A (ja) テトラヒドロピラン−４−オン化合物の製法
US9533956B2 (en) Method of manufacturing pyridazinone compound
MX2012008152A (es) Proceso para preparar voriconazol utilizando nuevos intermediarios.
CN110386891B (zh) 一种艾瑞昔布的制备方法
JPWO2006109570A1 (ja) ２−イソプロペニル−５−メチル−４−ヘキセン−１−イル３−メチル−２−ブテノアートの製造方法
WO2006024630A8 (en) Process for the production of [2- (4-fluoro-benzyl) -phenyl] -acetic acid
JP4983112B2 (ja) ３−（ヒドロキシ又はアルコキシ）−４−アルコキシ−６−ニトロ安息香酸化合物の製法
JP2008120759A (ja) エーテル基を有するβ−ジケトン化合物の製造法
WO2016158365A1 (ja) ３，３－ジフルオロ－２－ヒドロキシプロピオン酸の実用的な製造方法
CN117586177A (zh) 一种阿维巴坦中间体的制备方法

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application